ARS Pharmaceuticals, Inc. SPRY

SPRY Company Overview

ARS Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. The company operates within the biotechnology and specialty pharmaceutical industries, with a primary emphasis on needle-free emergency therapies. Its core commercial product is neffy, an intranasal epinephrine spray designed as an alternative to traditional injectable epinephrine auto-injectors for the emergency treatment of Type I allergic reactions, including anaphylaxis. Revenue generation is currently centered on commercialization activities tied to neffy, regulatory milestones, licensing arrangements, and related commercialization partnerships.

The company was founded to address barriers associated with injectable epinephrine products, including needle aversion, portability, and inconsistent patient usage during emergencies. ARS Pharmaceuticals evolved from a clinical-stage development company into a commercial-stage organization following U.S. regulatory approval of neffy in 2024. The company’s strategic positioning is based on proprietary intranasal drug delivery technology intended to improve accessibility and patient adherence in emergency allergy treatment settings.